Simcere Pharmaceutical Group Limited (FRA:S2P)

Germany flag Germany · Delayed Price · Currency is EUR
1.350
-0.020 (-1.46%)
Last updated: Sep 30, 2025, 8:03 AM CET
-1.46%
Market Cap3.58B
Revenue (ttm)844.70M
Net Income (ttm)104.62M
Shares Outn/a
EPS (ttm)0.04
PE Ratio34.24
Forward PE24.00
Dividend0.02 (1.41%)
Ex-Dividend DateJun 18, 2025
Volumen/a
Average Volume147
Open1.350
Previous Close1.370
Day's Range1.350 - 1.350
52-Week Range0.720 - 1.600
Betan/a
RSI46.25
Earnings DateNov 14, 2025

About FRA:S2P

Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENW... [Read more]

Industry Pharmaceutical Preparations
Founded 1995
Employees 6,584
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol S2P
Full Company Profile

Financial Performance

In 2024, FRA:S2P's revenue was 6.64 billion, an increase of 0.41% compared to the previous year's 6.61 billion. Earnings were 733.17 million, an increase of 2.57%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.